- Previous Close
6.70 - Open
6.75 - Bid 6.60 x --
- Ask --
- Day's Range
6.30 - 6.75 - 52 Week Range
6.30 - 9.50 - Volume
10 - Avg. Volume
13 - Market Cap (intraday)
32.099M - Beta (5Y Monthly) -0.06
- PE Ratio (TTM)
-- - EPS (TTM)
-0.08 - Earnings Date Mar 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.
www.daxor.comRecent News: DX5.F
View MorePerformance Overview: DX5.F
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DX5.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DX5.F
View MoreValuation Measures
Market Cap
34.14M
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.13
Price/Book (mrq)
1.02
Enterprise Value/Revenue
18.03
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
448.01%
Return on Assets (ttm)
-2.51%
Return on Equity (ttm)
1.54%
Revenue (ttm)
119.71k
Net Income Avi to Common (ttm)
536.33k
Diluted EPS (ttm)
-0.08
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
2.04%
Levered Free Cash Flow (ttm)
308.95k